Holen Sie sich die Stockscreener-App
155.63
0.39%
0.61
Vorhandelsmarkt:
155.51
-0.12
-0.08%
Schlusskurs vom Vortag:
$155.02
Offen:
$155.87
24-Stunden-Volumen:
948.90K
Relative Volume:
1.00
Marktkapitalisierung:
$15.52B
Einnahmen:
$2.41B
Nettoeinkommen (Verlust:
$305.80M
KGV:
52.76
EPS:
2.95
Netto-Cashflow:
$492.20M
1W Leistung:
+2.42%
1M Leistung:
+3.74%
6M Leistung:
+24.73%
1J Leistung:
+20.68%
1-Tages-Spanne:
$151.59
$156.69
1-Wochen-Bereich:
$151.01
$160.18
52-Wochen-Spanne:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
155.63 | 15.46B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
118.07 | 51.01B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.37 | 45.05B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.46 | 41.46B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.80 | 32.77B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
484.86 | 20.51B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
How Neurocrine Biosciences Inc. (NBIX) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Neurocrine Biosciences chief legal officer Lippoldt sells $698k in stock - Investing.com Canada
Neurocrine Bio. stock rating reiterated at Buy by TD Cowen - Investing.com UK
Neurocrine Biosciences Insider Sold Shares Worth $698,615, According to a Recent SEC Filing - marketscreener.com
Neurocrine Biosciences to Host R&D Day on December 16 - PR Newswire
Arrowstreet Capital Limited Partnership Acquires 58,562 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
RBC Capital Maintains Neurocrine Biosciences (NBIX) Outperform Recommendation - Nasdaq
RBC Capital Initiates Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $180 - 富途牛牛
Neurocrine Biosciences (NASDAQ:NBIX) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Neurocrine Biosciences stock hits 52-week high at $157.88 By Investing.com - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $180.00 - MarketBeat
Neurocrine Biosciences stock hits 52-week high at $157.88 - Investing.com
RBC Raises Price Target on Neurocrine Biosciences to $180 From $160, Keeps Outperform Rating - marketscreener.com
Hood River Capital Management LLC Sells 79,626 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Bio. stock price target raised to $180 from $160 at RBC Capital - Investing.com
Neurocrine Biosciences (NBIX) valuation update after NBI-1070770 Phase 2 trial failure reshapes pipeline expectations - simplywall.st
Earnings Recap: How Neurocrine Biosciences Inc stock performs in weak economyWeekly Trade Report & High Accuracy Trade Alerts - BỘ NỘI VỤ
TD Cowen Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Growth Value: How MSPRO stock compares to industry benchmarksQuarterly Performance Summary & AI Powered Market Entry Strategies - BỘ NỘI VỤ
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Brown Advisory Inc. - MarketBeat
TD Cowen Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq
Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level - Investor's Business Daily
Saturn V Capital Management LP Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Will Neurocrine Biosciences Inc. stock split again soonWeekly Loss Report & Free Fast Gain Swing Trade Alerts - Newser
Neurocrine Bio. stock price target raised to $200 from $175 at TD Cowen By Investing.com - Investing.com South Africa
Neurocrine Bio. stock price target raised to $200 from $175 at TD Cowen - Investing.com India
Why Neurocrine Biosciences Inc. (NB3) stock stays on buy listsPortfolio Gains Summary & High Accuracy Trade Signal Alerts - Newser
Dodge & Cox Increases Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
U.S. Tardive Dyskinesia Treatment Market to Reach USD 6417.43 - openPR.com
Will Neurocrine Biosciences Inc. (NB3) stock beat growth indexesOil Prices & Accurate Technical Buy Alerts - Newser
Is Neurocrine Biosciences Stock Built to Withstand a Pullback? - Trefis
Lyons (Neurocrine Biosciences director) sells $2.29m in NBIX stock - Investing.com
Neurocrine Biosciences Insider Sold Shares Worth $2,289,083, According to a Recent SEC Filing - marketscreener.com
Dir Lyons Sells 15,000 ($2.3M) Of Neurocrine Biosciences Inc [NBIX] - TradingView
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockWeekly Trend Summary & Real-Time Buy Zone Alerts - Newser
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyDollar Strength & Growth Oriented Trade Recommendations - Newser
Will Neurocrine Biosciences Inc. (NB3) stock split increase liquidityDividend Hike & Precise Entry and Exit Recommendations - Newser
Will Neurocrine Biosciences Inc. (NB3) stock benefit from sector leadershipPortfolio Profit Report & Expert Verified Stock Movement Alerts - Newser
Will Neurocrine Biosciences Inc. (NB3) stock gain from green policies2025 Institutional Moves & Weekly High Potential Alerts - Newser
Why Neurocrine Biosciences Inc. (NB3) stock remains top ratedMarket Trend Summary & Daily Technical Forecast Reports - Newser
Fisher Asset Management LLC Trims Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Earnings Notes - Trefis
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? - The Motley Fool
Dir Lyons Files To Sell 15,000 Of Neurocrine Biosciences Inc [NBIX] - TradingView
Sio Capital Management LLC Lowers Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Mackenzie Financial Corp Has $9.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Norges Bank Takes Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Hsbc Holdings PLC - MarketBeat
Korea Investment CORP Cuts Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Russell Investments Group Ltd. Has $10.58 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Can Neurocrine Biosciences Inc. stock attract ESG capital inflowsJuly 2025 Drop Watch & Consistent Growth Stock Picks - Newser
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
4.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):